Clear Aligners vs. Implants: Which Service Line Actually Moves a DSO's Bottom Line?

Every DSO operator eventually asks the same question: where should the next dollar of clinical capacity go? Two answers dominate the conversation — clear aligners and implants — and both are frequently pitched as the highest-margin, fastest-payback service lines available to a multi-location group. Both claims are true. They are just true in different ways, on different timelines, and with different operational demands.

This is a side-by-side, numbers-first comparison built for DSO operators, PE-backed platform CFOs, and practice owners evaluating where to deploy capital and provider time. Every figure below is sourced and linked in the references section so it can be independently verified.

Why Service-Line Diversification Is an EBITDA Question, Not a Clinical One

Roughly 15–20% of U.S. dentists now practice within the DSO model, and the segment's growth has made service-line strategy a core underwriting question for buyers, not a back-office decision for clinical directors. DSO platform multiples currently sit in a 10.0x–13.0x adjusted EBITDA band, while specialty-heavy practices — those that keep orthodontic, endodontic, and implant cases in-house rather than referring them out — command a structural premium, with specialty platforms trading at 10x–14x+ EBITDA in 2026 and orthodontic-heavy groups commanding roughly 1.0 to 3.0 turns above an equivalent-sized general practice baseline.

That premium exists because M&A advisors and buyers explicitly screen for it. In a widely cited 2026 interview, a DSO M&A advisor identified integrated specialty services — keeping ortho, endo, and implant cases in-house instead of referring them out — alongside clear aligner programs, patient financing, and membership plans as the operational markers that separate acquisition targets buyers compete for from ones they pass on. In other words, referral leakage isn't just lost production; it's a multiple-compressing signal at exit.

The leakage math is stark at scale. One industry analysis modeled a single location referring out orthodontic cases at a conservative 10% conversion rate and a $4,500 average case value — that alone represents roughly $297,000 in annual orthodontic revenue walking out the door. Multiply that across a 20-location DSO and the group is referring away nearly $6 million a year. Push conversion to a still-modest 15%, which active patient communication programs routinely achieve, and that same 20-location group captures over $9 million annually. This is the frame that should govern the clear aligner vs. implant decision: it isn't which service is "better," it's which one converts more of the demand already sitting in your existing patient panel, at what cost, and on what timeline.

Clear Aligners: Fast Ramp, High Margin, Thin Capital Requirement

Clear aligners are the lower-friction of the two service lines to launch, and the numbers explain why so many DSOs treat them as the first rung on the specialty ladder.

Market tailwind. The global aligner therapy market was valued at $4.5 billion in 2024 and is projected to reach $9.2 billion by 2030, a 16.8% CAGR, with the U.S. alone generating $1.9 billion in 2024 and North America accounting for roughly 42% of global revenue. Demand-side research from the American Association of Orthodontists found that 52% of adults are at least somewhat interested in teeth straightening, and 78% of that group prefers aligner therapy over traditional braces — meaning the patient demand is already sitting in general and hygiene chairs across a DSO's network.

Margin structure. Aligner cases carry gross margins in the 55–70% range industry-wide — among the highest of any general dentistry service line — and DSOs that bring treatment planning and manufacturing fully in-house (via platforms such as Ormco Spark or in-office 3D printing) can push gross margins to 70–80% per case, though that route requires $40,000–$80,000 in upfront equipment investment plus staff training. The more common outsourced-lab model requires a smaller lift: practices typically break even on the $15,000–$25,000 training and setup investment after 8–12 cases, and most reach profitability within 90 days of launch.

Case acceptance is the real lever. Industry-average case acceptance for clear aligners runs 25–35%, but top-performing practices achieve 50–60% through structured consultation processes, visual treatment simulation, and confident case presentation — meaning the difference between a mediocre and an excellent aligner program is almost entirely an execution variable, not a clinical or capital one.

DSO-scale effects are non-linear. Because aligner workflows can be standardized across locations — shared scanning protocols, a common case-selection framework, and a centralized treatment-planning review pathway — DSOs that launch a unified, group-level aligner program across 20 or more locations have seen systemwide orthodontic case volume increase 35–50% within 18 months, a result that would take a solo practice years to replicate organically. Centralized brand marketing also lets a DSO route orthodontic demand to whichever location has open capacity, rather than losing the patient to a competitor down the street.

Implants: Higher Case Value, Longer Ramp, Bigger Capital and Training Commitment

Implants sit at the opposite end of the operational-complexity spectrum from aligners, but the per-case economics are difficult to match.

Revenue concentration. A single implant case generates $1,500–$6,000 in revenue, which industry benchmarking puts at the equivalent of 15–30 routine cleanings — meaning a modest increase in monthly implant volume can move practice-level revenue more than a proportional increase in patient count ever could. Direct costs (the fixture, surgical materials, and lab work) typically run $800–$2,500 per case, producing a 30–50% profit margin that holds up even after accounting for the specialized equipment and continuing education implant dentistry requires.

Provider-level productivity. Providers who perform implants and other advanced procedures in-house — rather than referring them to a specialist — see materially higher revenue per provider than colleagues who refer those cases out, and dedicated implant specialists generate $1.5–2 million in annual practice revenue per provider. At the practice level, implant-focused benchmarking shows roughly $232,000 in annual revenue per operatory and $977,000 per provider, with operating margins in the 30–40% range — comparable to general practice margins but on a meaningfully larger revenue base per chair.

Demand is structural, not cyclical. The U.S. dental implant market was valued at approximately $1.83 billion in 2025 and is projected to reach $4.61 billion by 2035 (a 9.68% CAGR), while the global market is expected to grow from $5.6 billion in 2025 to $11.0 billion by 2033. That growth is demographic, not discretionary: the American College of Prosthodontists estimates 120 million Americans are missing at least one tooth and more than 36 million are fully edentulous, and the World Health Organization puts global complete-tooth-loss prevalence at roughly 23% among adults 60 and older. Annual U.S. implant placement volume is expected to exceed 500,000 procedures by 2026, with success rates consistently above 95–98% supporting continued patient acceptance. This is a multi-decade demand curve, not a trend that plateaus with the next generation of aligner marketing.

The ramp is real. Implants demand a materially higher clinical and capital bar than aligners: CBCT imaging, guided-surgery equipment, surgical credentialing or continuing education, and — for many GP-model DSOs — the choice between training general dentists to place implants versus recruiting or partnering with a periodontist or oral surgeon. That is a longer runway to first-case revenue than an aligner launch, even though the per-case payoff is larger once the program is running at volume.

Head-to-Head: The Numbers That Matter for Underwriting

The honest read of this table: aligners win on speed, margin percentage, and scalability across a network; implants win on absolute case value, provider-level revenue concentration, and the durability of the underlying demographic demand curve. Neither is a substitute for the other — they solve different capacity and margin problems.

Sequencing the Rollout: A Portfolio, Not a Bet

Most DSOs that get this right treat it as sequencing, not a single choice.

1. Launch aligners first where general dentists already have chair capacity. The lower capital bar and faster breakeven make aligners the more forgiving service line to standardize across a network before layering in a bigger clinical investment. Given industry-average case acceptance of only 25–35%, the first operational win is usually training front-desk and clinical teams on case presentation, not the clinical protocol itself.
2. Audit implant referral leakage before building implant capacity. Before investing in CBCT equipment or surgical training, quantify how many implant-eligible patients are currently being referred externally. That number — multiplied across locations — is the business case for building the service line in-house rather than continuing to send patients (and margin) to outside specialists.
3. Standardize before you scale either one. Aligner workflows and implant case-selection criteria both need a shared protocol — what a location treats routinely, what requires additional provider experience, and what gets referred to a more specialized workflow internally — before a multi-location rollout, or outcomes and patient experience will vary by office and undermine the brand-level marketing advantage a DSO is supposed to have.
4. Treat the accounting separately, especially for aligners. Aligner and other cash-pay retail revenue is typically 100% self-pay and tracked outside standard clinical billing workflows. Without disciplined categorization, that revenue can be misclassified or inconsistently recognized, which obscures true service-line profitability and creates audit-readiness problems heading into a recapitalization or sale.

Operational Risks to Underwrite Before You Launch Either One

The revenue and margin figures above are achievable, but they are not automatic. Three risks show up repeatedly in DSOs that struggle to hit the benchmarks.

Case-acceptance execution, not clinical capability, is usually the bottleneck for aligners. The gap between the industry-average 25–35% case acceptance rate and the 50–60% top-performer rate has almost nothing to do with clinical skill and almost everything to do with consultation process — dedicated consultation space, visual treatment simulation, and confident case presentation. A DSO that trains providers on the clinical protocol but skips the front-desk and treatment-coordinator training on case presentation will underperform the margin numbers by a wide margin, even with a technically excellent aligner program.

Training debt is the most underestimated cost in both service lines. For aligners, practices that skip adequate clinical training tend to produce poorer outcomes, generate more refund requests, and take a reputational hit in a category where patient satisfaction drives a large share of new referrals. For implants, the stakes are higher still: the difference between a general dentist confidently placing straightforward single-tooth implants and one who is undertrained is not just a margin question but a liability and outcomes question. Budgeting real continuing-education time and cost — not just equipment capital — is what separates programs that hit benchmark margins from ones that never ramp past a handful of cases per month.

Consistency across locations is what protects the brand-level payoff. A DSO's structural advantage over a solo practice is the ability to run one marketing campaign, one patient communication cadence, and one case-selection protocol across every location and capture the benefit everywhere at once. That advantage disappears the moment case-selection criteria vary office to office — one location declining cases another location routinely accepts creates inconsistent patient experience, undermines online reviews, and makes forecasting capacity and staffing far less reliable at the network level. Building a shared protocol that defines which cases a location treats routinely, which require additional provider experience, and which get referred internally to a more specialized workflow is what makes the standardization payoff real rather than theoretical.

Frequently Asked Questions

Which has a faster payback, clear aligners or implants?
Clear aligners typically break even faster — most practices recover the $15,000–$25,000 training and setup investment within 8–12 cases, often inside 90 days of launch. Implants have a longer runway to first-case revenue because of equipment, credentialing, and case-flow ramp-up, even though per-case value is often comparable or higher.

Do implants or aligners have higher profit margins?
Aligners generally carry a higher margin percentage — 55–70% gross margin industry-wide, and up to 70–80% with in-house manufacturing. Implants run 30–50% margins, but on a higher absolute case value, so the dollar profit per case can be comparable or greater despite the lower percentage.

Why do implants and aligners affect a DSO's valuation, not just its revenue?
Buyers and M&A advisors treat in-house specialty capability — keeping ortho, endo, and implant cases internal rather than referring them out — as a specific underwriting criterion. Specialty-heavy platforms trade at a structural premium (10x–14x+ EBITDA versus a 10.0x–13.0x general baseline), so building these service lines in-house is as much a multiple-expansion strategy as a revenue strategy.

How much revenue is a DSO typically losing to referral leakage?
Modeling from a 20-location DSO referring out orthodontic cases at a conservative 10% conversion rate and $4,500 average case value shows roughly $6 million in annual revenue referred away. Improving conversion to 15% — achievable with structured patient communication — captures more than $9 million annually for the same network.

Should a smaller DSO or single practice do both at once?
Sequencing usually outperforms doing both simultaneously. Aligners are the lower-capital, faster-payback entry point that builds internal case-acceptance and treatment-planning muscle; implant capacity is best built once referral-leakage data justifies the larger equipment and training investment.

The Bottom Line

Clear aligners and implants aren't competing line items on a DSO's growth plan — they're complementary answers to the same underlying question: how much of the specialty demand already inside your patient panel is currently walking out the door to a competitor or an outside specialist? Aligners capture that demand faster and at a lower capital cost. Implants capture more dollars per case against a demand curve that will keep growing for decades as the population ages. A DSO that sequences both, standardizes the clinical protocols across locations, and tracks the resulting cash-pay revenue with real accounting discipline is the one that shows up on the buy side of the next roll-up — not the sell side.

References

1. Dentimax, "Average Dental Office Revenue: 2026 Data & Benchmarks" — https://dentimax.com/average-dental-office-revenue-2026-data-benchmarks/
2. DojoBusiness, "Dental Procedures: Profit Margin Estimation" — https://dojobusiness.com/blogs/news/dental-clinic-profit-margins-estimate
3. DentalPrice.AI, "Dental Implant Clinic Performance Metrics in the United States (2023–2024)" — https://blog.dentalprice.ai/dental-implant-clinic-performance-metrics-in-the-united-states-2023-2024/
4. DentalPrice.AI, "Dental Implant Practice Benchmarks 2023–2024" — https://dentalprice.ai/blog/dental-implant-clinic-metrics/
5. Dental Practice Insider, "Clear Aligner Profitability: Is It Worth Adding to Your Practice?" — https://dentalpracticeinsider.org/clear-aligner-profitability-analysis/
6. Group Dentistry Now, "The Orthodontic Revenue You're Already Sitting On" — https://www.groupdentistrynow.com/dso-group-blog/dental-growth/
7. Clear Moves Aligners, "Clear Aligners for DSOs" — https://clearmovesaligners.com/clear-aligners-for-dsos/
8. Clear Moves Aligners, "How Clear Aligners Increase Dental Practice Revenue by 40%" — https://clearmovesaligners.com/how-clear-aligners-increase-dental-practice-revenue-by-40/
9. CT Acquisitions, "Dental and DSO M&A Multiples Report 2026" — https://ctacquisitions.com/guides/dental-dso-ma-multiples-2026/
10. CT Acquisitions, "Dental DSO PE Roll-Up Tracker: 2026 Platforms" — https://ctacquisitions.com/dental-dso-pe-rollup-tracker-2026/
11. The Daily Tooth, "All Things DSO: EBITDA, Overhead, and Opportunity" — https://blog.emergencydentalservice.com/all-things-dso-ebitda-overhead-and-opportunity/
12. VMG Health, "Why Quality of Revenue Matters More Than EBITDA in DSO Strategy" — https://vmghealth.com/insights/blog/why-quality-of-revenue-matters-more-than-ebitda-in-dso-strategy/
13. Solventum, "Operationalizing Clear Aligners in a DSO: Standardization Across Locations" — https://www.solventum.com/en-us/home/oral-care/brain-floss/blog/2026/7/Operationalizing-Clear-Aligners-in-a-DSO-Standardization-Across-Locations/
14. Grand View Research, "Dental Implants Market Size & Share Report, 2026–2033" — https://www.grandviewresearch.com/industry-analysis/dental-implants-market
15. Precedence Research, "Dental Implants Market Size, Share and Trends 2026 to 2035" — https://www.precedenceresearch.com/dental-implants-market
16. GM Insights, "Dental Implants Market Size, Share & Forecast, 2026–2035" — https://www.gminsights.com/industry-analysis/dental-implants-market
17. DSM Cosmetic Dentist, "Dental Implant Statistics in the U.S.: Dentistry Report 2026" — https://www.dsmcosmeticdentist.com/dental-implant-statistics/
18. Imagine Your Smile, "Dental Implant Demand Statistics: 2026 Dentistry Report" — https://www.imagineyoursmile.com/blog/dental-implant-demand-statistics/